Genetic Physiopathology and Evolution of Type 2 Diabetes (GENFIEV)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00879801|
Recruitment Status : Completed
First Posted : April 10, 2009
Last Update Posted : April 10, 2009
There are few longitudinal studies in the Caucasian population and even less in the Italian population in subjects with impaired glucose regulation to allow:
- An estimate of the rate of conversion to type 2 diabetes;
- To identify subjects at risk; and
- To assess the physiopathologic mechanisms responsible for the conversion.
In order to set up a longitudinal study capable of defining the above parameters it is mandatory that the physiological, biochemical, and, genetic markers specific for IGR are identified. The goals of the present research proposal are:
- To clarify the physiological mechanisms responsible for IGR;
- To identify the biochemical and beta-cell auto-immune parameters present in IGR;
- Identify genetic markers.
The subjects who will be identified will add up to other 900 individuals who will be recruited as part of a follow-up program sponsored by the Italian Society of Diabetes, specifically designed to assess conversion rate to diabetes.
|Condition or disease|
The main goal of the present research program is to recruit about 600 new subjects with IGR to be added to the 900 subjects which are collected as part of the GENFIEV project which has been designed as a 6-yr follow-up study to ascertain the rate of conversion to type 2 diabetes in the Italian population. In particular the goal of the present research program will be to determine in a sample of the Italian population at greater risk for type 2 diabetes than the general population:
- the pathophysiologic mechanisms responsible for the disorders of impaired glucose regulation (IGR). In particular we will evaluate insulin action and insulin secretion as a function of the degree of glucose tolerance by analyzing these parameters in normal subjects as well as in IFG/NGT, NFG/IGT, and IFG/IGT individuals;
- the biochemical markers associated with the disorders of impaired glucose regulation (IGR). In particular we will evaluate several biochemical parameters (lipid profile, coagulative profile, microlbuminuria, free-fatty acids, PAI-1, fibrinogen, creatinine, uric acid, HbA1c);
- the cardiovascular risk profile associated with the disorders of impaired glucose regulation (IGR). In particular, the relevant biochemical parameters will be integrated with measurements of arterial blood pressure as well as ECG recording;
- the genetic markers associated with the disorders of impaired glucose regulation (IGR). In particular subjects will be screened for HHEX, IGF2,BP2 CDKAL1,TCF2L7, CDKN2A/B,WFS1;
- the impact of environmental factors on the disorders of impaired glucose regulation (IGR).
Finally, we will endeavour to assess the cellular pathways that may be affected by metabolic alterations typically occurring in concomitance with the disorders of impaired glucose regulation (IGR).
|Study Type :||Observational|
|Actual Enrollment :||1017 participants|
|Official Title:||Evaluation of Genetic, Biochemical and Clinical Determinants of Type 2 Diabetes Progression in Subjects at High Risk|
|Study Start Date :||January 2003|
|Actual Primary Completion Date :||December 2008|
|Actual Study Completion Date :||December 2008|
Subjects with IGR
Subjects at high risk of diabetes, such as those with impaired glucose regulation (IFG and or IGT)
- The rate of conversion to diabetes of IGR subjects carrier of type 2 diabetes susceptibility genes [ Time Frame: December 2009 ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00879801
|Department of Endocrinology and Metabolism, University of Pisa|